Takara Bio Inc.: Business Overview, Financials & Competitive Analysis
Takara Bio Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Positioned for growth in expanding gene therapy markets with proprietary platforms and manufacturing infrastructure, though near-term profitability recovery is critical. Takara Bio holds a strong position in gene therapy and life science research with first-mover advantages in Japan's gene therapy space and a robust CDMO infrastructure. However, profitability challenges.
What is Takara Bio Inc.'s industry? Takara Bio Inc. (takara-bio.co.jp) operates in Biotechnology & Gene Therapy. AskCyborg classifies Takara Bio Inc. under Biotechnology & Gene Therapy in its company registry.
Takara Bio is a biotechnology company that develops and researches reagents for genome engineering and analysis, the technology used for gene therapy and natural health food products. The company reports in three busi...
Cyborg Score thesis
Positioned for growth in expanding gene therapy markets with proprietary platforms and manufacturing infrastructure, though...
Read the full analyst-debate transcript →Get the Latest Takara Bio Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTakara Bio Inc. Overview
Pro stress-test →Takara Bio is a biotechnology company that develops and researches reagents for genome engineering and analysis, the technology used for gene therapy and natural health food products. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio.
Strategic Profile
Pro stress-test →Takara Bio became the first company in Japan to conduct clinical trials of gene therapy products in 2008 and entered the CDMO business early, operating the Center for Gene and Cell Processing (CGCP), a large-scale one-stop center for development, manufacturing, and quality testing of gene therapy products. The company develops and delivers products tailored to local researchers through manufacturing centers in the U.S., Europe, China, and India, along with a global sales network.
Competitive Landscape
Pro stress-test →Takara Bio competes in the biotechnology research reagent and gene therapy manufacturing space against companies like Thermo Fisher, FUJIFILM Cellular Dynamics, and emerging CDMO players. Its competitive advantages include early entry into Japan's gene therapy market, established CDMO infrastructure, and a comprehensive portfolio of research reagents.
Industry Context
Takara Bio Inc. operates in Biotechnology & Gene Therapy.
Key facts
Founded: 2002 · Headquarters: Kusatsu, Japan · Employees: 1,779 · Revenue: $311.7M · Market cap: $891.6M